Abstract:The case-cohort study design combines the advantages of a cohort study with the efficiency of a nested case-control study. However, unlike more standard observational study designs, there are currently no guidelines for reporting results from case-cohort studies. Our aim was to review recent practice in reporting these studies, and develop recommendations for the future. By searching papers published in 24 major medical and epidemiological journals between January 2010 and March 2013 using PubMed, Scopus and W… Show more
Omentin is a novel biomarker shown to exert metabolic, inflammatory, and immune-related properties and thereby could be implicated in the risk of colorectal cancer. So far, the association between omentin and colorectal cancer risk has not been evaluated in prospective cohort studies. We investigated the association between prediagnostic plasma omentin concentrations and risk of colorectal cancer in a case-cohort comprising 251 incident colorectal cancer cases diagnosed over a mean follow-up time of 10.4 years and 2,295 persons who remained free of cancer in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. Hazard ratios as a measure of relative risk (RR) and 95% confidence intervals (CI) were computed using a Prentice-modified Cox regression. In a multivariable model adjusted for age, sex, education, dietary and lifestyle factors, body mass index (BMI), and waist circumference, higher omentin concentrations were associated with a higher colorectal cancer risk (RR continuously per doubling of omentin concentrations ¼ 1.98; 95% CI, 1.45-2.73). Additional adjustment for metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholesterol, and C-reactive protein, did not alter the results. In stratified analyses, the positive association between omentin and colorectal cancer risk was retained in participants with BMI < 30 (RR continuously per doubling of omentin concentrations ¼ 2.26; 95% CI, 1.57-3.27), whereas among participants with BMI ! 30 no association was revealed (RR continuously per doubling of omentin concentrations ¼ 1.07; 95% CI, 0.63-1.83; P interaction ¼ 0.005). These novel findings provide the first lines of evidence for an independent association between prediagnostic omentin concentrations and colorectal cancer risk and suggest a potential interaction with the adiposity state of the individual. Cancer Res; 76(13); 3862-71. Ó2016 AACR.
Omentin is a novel biomarker shown to exert metabolic, inflammatory, and immune-related properties and thereby could be implicated in the risk of colorectal cancer. So far, the association between omentin and colorectal cancer risk has not been evaluated in prospective cohort studies. We investigated the association between prediagnostic plasma omentin concentrations and risk of colorectal cancer in a case-cohort comprising 251 incident colorectal cancer cases diagnosed over a mean follow-up time of 10.4 years and 2,295 persons who remained free of cancer in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. Hazard ratios as a measure of relative risk (RR) and 95% confidence intervals (CI) were computed using a Prentice-modified Cox regression. In a multivariable model adjusted for age, sex, education, dietary and lifestyle factors, body mass index (BMI), and waist circumference, higher omentin concentrations were associated with a higher colorectal cancer risk (RR continuously per doubling of omentin concentrations ¼ 1.98; 95% CI, 1.45-2.73). Additional adjustment for metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholesterol, and C-reactive protein, did not alter the results. In stratified analyses, the positive association between omentin and colorectal cancer risk was retained in participants with BMI < 30 (RR continuously per doubling of omentin concentrations ¼ 2.26; 95% CI, 1.57-3.27), whereas among participants with BMI ! 30 no association was revealed (RR continuously per doubling of omentin concentrations ¼ 1.07; 95% CI, 0.63-1.83; P interaction ¼ 0.005). These novel findings provide the first lines of evidence for an independent association between prediagnostic omentin concentrations and colorectal cancer risk and suggest a potential interaction with the adiposity state of the individual. Cancer Res; 76(13); 3862-71. Ó2016 AACR.
“…In case-cohort studies, stratified selection of the subcohort seems to be common (Sharp et al, 2014), so there are likely to be plenty of investigations where cchs may be useful. The way in which cchs manipulates the data makes it faster and more computationally efficient than the previously published SAS and S-Plus code.…”
Section: Discussionmentioning
confidence: 99%
“…The subcohort is about half as big as the set of cases. In case-cohort studies in general, the sampling fraction is typically in the area of 5% but sometimes larger (Sharp et al, 2014), and the subcohort is usually larger than the set of cases (Juraschek et al, 2013;Lamb et al, 2013;Jones et al, 2015) but occasionally smaller (Huxley et al, 2013).…”
The cchs package contains a function, also called cchs, for analyzing data from a stratified case-cohort study, as used in epidemiology. For data from this type of study, cchs calculates Estimator III of Borgan et al. (2000), which is a score-unbiased estimator for the regression coefficients in the Cox proportional hazards model. From the user's point of view, the function is similar to coxph (in the survival package) and other widely used model-fitting functions. Convenient software has not previously been available for Estimator III since it is complicated to calculate. SAS and S-Plus code-fragments for the calculation have been published, but cchs is easier to use and more efficient in terms of time and memory, and can cope with much larger datasets. It also avoids several minor approximations and simplifications.
“…If multiple imputation was used with Model V, it would need to be done in each stratum separately, using Rubin's rules, before the meta-analysis [20] . We have only considered methods based on Cox regression, with a nonparametric baseline hazard, since these seem to be used almost exclusively in practice [21] , but parametric survival models for stratified case–cohort studies could be developed. These might have particular relevance for risk prediction [22] , whereas the focus of this article has been on estimating the risk association of a particular exposure.…”
ObjectiveA case–cohort study is an efficient epidemiological study design for estimating exposure–outcome associations. When sampling of the subcohort is stratified, several methods of analysis are possible, but it is unclear how they compare. Our objective was to compare five analysis methods using Cox regression for this type of data, ranging from a crude model that ignores the stratification to a flexible one that allows nonproportional hazards and varying covariate effects across the strata.Study Design and SettingWe applied the five methods to estimate the association between physical activity and incident type 2 diabetes using data from a stratified case–cohort study and also used artificial data sets to exemplify circumstances in which they can give different results.ResultsIn the diabetes study, all methods except the method that ignores the stratification gave similar results for the hazard ratio associated with physical activity. In the artificial data sets, the more flexible methods were shown to be necessary when certain assumptions of the simpler models failed. The most flexible method gave reliable results for all the artificial data sets.ConclusionThe most flexible method is computationally straightforward, and appropriate whether or not key assumptions made by the simpler models are valid.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.